Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy

Hepatology

Volumn 26, Issue 6, 1997, Pages 1410-1414

  Watanabe, Akiharu ^a   Sakai, Takahiro ^b   Sato, Shunichi ^c   Imai, Fukashi ^d   Ohto, Masao ^e   Arakawa, Yasuyuki ^f   Toda, Gotaro ^g   Kobayashi, Kenichi ^h   Muto, Yasutoshi ⁱ   Tsujii, Tadasu ^j   Kawasaki, Hironaka ^k   Okita, Kiwamu ^l   Tanikawa, Kyuichi ^m   Fujiyama, Shigetoshi ⁿ   Shimada, Shigehiko ^o  

^a UNIVERSITY OF TOYAMA   (Japan)

^b SAGA UNIVERSITY   (Japan)

^c IWATE MEDICAL UNIVERSITY   (Japan)

^d Department of Internal Medicine   (Japan)

^e CHIBA UNIVERSITY   (Japan)

^f NIHON UNIVERSITY   (Japan)

^g JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h KANAZAWA UNIVERSITY   (Japan)

ⁱ Giju University School of Medicine   (Japan)

^j NARA MEDICAL UNIVERSITY   (Japan)

^k TOTTORI UNIVERSITY   (Japan)

^l YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^m KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁿ KUMAMOTO UNIVERSITY   (Japan)

^o KITASATO UNIVERSITY HOSPITAL   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LACTULOSE;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FEMALE; GLUCOSURIA; HEPATIC ENCEPHALOPATHY; HUMAN; HYPERAMMONEMIA; INTELLIGENCE TEST; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL; SYRUP; VOMITING;

EID: 0030701641     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510260606     Document Type: Article

References (19)

1. Rikkers L, Jenko P, Rudman D, Freidas D. Subclinical hepatic encephalopathy detection, prevalence and relationship to nitrogen metabolism. Gastroenterology 1978;75:462-469.
2. Gitlin N. Subclinical portal-systemic encephalopathy. Am J Gastroenterol 1988;83:8-11.
3. Zeneroli ML, Cioni G, Uezzelli C, Grandi S, Crisi G, Luzietti R, Ventura E. Prevalence of brain atrophy in liver cirrhosis patients with chronic persistent encephalopathy. Evaluation by computed tomography. J Hepatol 1987;4:283-292.
4. O'Carroll RE, Hayes PC, Ebmeier KP, Dougall N, Murray C, Best JJ, Bouchier IR, et al. Regional cerebral blood flow and cognitive function in patients with chronic liver disease. Lancet 1991;37:1250-1253.
5. Watanabe A, Murakami J, Ando T, Hioki O, Wakabayashi H, Higuchi K. Reduction of increased signal intensity in the basal ganglia on T1-weighted MR images during treatment of hepatic encephalopathy. Int Med 1993;32:10-14.
6. Bircher J, Müller J, Guggenheim P, Haemmerli UP. Treatment of chronic portal systemic encephalopathy with lactulose. Lancet 1966;1:890-892.
7. Conn HO, Leevy CM, Vlahcevic ZR, Rodgers JB, Maddrey WC, Seeff L, Levy LL. Comparison of lactulose and neomycin in the treatment of chronic portal systemic encephalopathy. A double blind controlled trial. Gastroenterology 1977;72:573-583.
8. Takahashi Y, Shimizu M. Nation-wide investigation of fulminant hepatitis - definition and relationship between prognosis and days from the onset to the appearance of consciousness impairment. Proceed 12th Inuyama Symp., Chugai Igaku Co., Tokyo, Japan, 1982:116-125 [in Japanese].
9. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-649.
10. Shiota T. Quantitative psychometric testing and Subclinical hepatic encephalopathy - comparative study between encephalopathy and non-encephalopathic patients with liver cirrhosis. Acta Med Okayama 1984; 38:193-205.
11. Higuchi K, Shimizu Y, Numbu S, Miyabayashi C, Takahara T, Saito S, Hioki O, et al. Effects of an infusion of branched chain amino acids on neurophysiological and psychometric testings in cirrhotic patients with mild hepatic encephalopathy. J Gastroenterol Hepatol 1994;9:366-372.
12. Watanabe A, Tsuchida T, Yata Y, Kuwabara Y. Evaluation of neuropsychological function in patients with liver cirrhosis with special reference to their driving ability. Metabol Brain Res 1995;10:239-248.
13. McClain CJ, Potter TJ, Kromhout JP, Zieve L. The effect of lactulose on psychomoter performance tests in alcoholic cirrhosis without overt hepatic encephalopathy. J Clin Gastroenterol 1984;6:325-329.
14. Morgan MY, Alonso M, Stanger LC. Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy in cirrhotic patients. A randomized, cross-over study. J Hepatol 1989;8:208-217.
15. Quero JC, Groeneweg M, Meulstee J, Hop WCJ, Schalm SW. Does a low-dose of lactulose improve quality of life in patients with liver cirrhosis? In: Record H, ed. Advances in Hepatic Encephalopathy and Metabolism in Liver Disease. Boca Raton: CRC Press, 1997:459-465.
16. Sato S. Treatment of subclinical encephalopathy: lactulose. New Remedies and Therapy 1994;31:797-804 [in Japanese].
17. Quero JC, Hartmann IJC, Meulstee J, Hop WCJ, Schalm SW. The diagnosis of subclinical hepatic encephalopathy in patients with cirrhosis using neuropsychological tests and automated electroencephalogram analysis. HEPATOLOGY 1996;24:556-560.
18. Sagalés T, Gimeno V, de la Calzada MD, Casellas F, Dolors Maciá M, Villar Soriano M. Brain mapping analysis in patients with hepatic encephalopathy. Brain Topogr 1990;2:221-228.
19. Schomerus H, Hamster W, Blunck H, Reinhard U, Mayer K, Döll W. Latent portasystemic encephalopathy. I. Nature of cerebral functional defects and their effect on fitness to drive. Dig Dis Sci 1981;26:622-630.